A Phase 3 interventional study of Levetiracetam in Epilepsy and Generalized Tonic-clonic Seizures, sponsored by UCB Pharma. Completed at 32 sites in Japan. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2017-08-15.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies testing levetiracetam in Epilepsy — 4 open to participants now, 4 under way, 2 of them phase 3. Levetiracetam · Epilepsy.
Among the 60 studies testing levetiracetam in Epilepsy, this one is the 36th largest by enrollment, is one of 5 that started in 2011, is one of 28 in phase 3, and was the 42nd registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →4 of the 60 studies testing levetiracetam in Epilepsy are open now, in 3 countries. Recruiting first, the newest first:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain
Ages 40+
Waad Alkathiri · Sites in Saudi Arabia
Ages 18+
Xiangya Hospital of Central South University · Sites in China
Ages 18–80
National Taiwan University Hospital
Ages 20+
By country, each count listing its studies:
Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 4 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 13 · Phase 3 28 · Phase 4 13
First in 1998; this study’s year is marked. 5 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 44 is below the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 94 across the 60 interventional studies. Of the 55 that completed or were terminated, 31 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 60 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
128 studies in Epilepsy by UCB S.A.: 1 open now, 2 under way, 2 of them phase 3. Of 121 finished, 90 (74%) have results posted.
Among the 128 studies in Epilepsy by UCB S.A., this one is the 83rd largest by enrollment of the 116 interventional ones that give a count, is one of 13 that started in 2011, is one of 74 in phase 3, and was the 75th registered.
UCB S.A.’s Epilepsy studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 60 studies testing levetiracetam in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 128 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The investigators will provide Levetiracetam treatment to epilepsy subjects in Japan who are judged to benefit from continued treatment with Levetiracetam by the investigators and who are willing to continuously receive this drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Twice daily (morning and evening) orally
Drug: Levetiracetam
formulation: tablet or dry syrup strength: 250 mg tablet, 500 mg tablet, dry syrup 50% dosage: Sb ≥16 years and ≥4 and \<16 years (≥50 kg): 1000 mg/day, 2000 mg/day or 3000 mg/day; Sb ≥4 and \<16 years (\<50kg): 20 mg/kg/day, 40 mg/kg/day, or 60 mg/kg/day frequency: twice daily
Also known as: Keppra, E Keppra
Incidence of Treatment Emergent Adverse Events During the Entire Study Period
Time frame: Through study completion, an average of 3 years
The Percentage Change in Generalized Tonic-Clonic (GTC) Seizure Frequency Per Week Over the Evaluation Period From Either of the Combined Baseline Periods of the Previous Studies (N01159 or N01363).
Percentage change in generalized tonic-clonic (GTC) seizure frequency per week from Baseline of previous studies B over the Treatment Period A is calculated using the equation: Percentage change from Baseline = ((A-B)/B)\*100. Percentage change from baseline is not defined for subjects whose baseline information is missing / unknown or equal to zero, or whose seizure frequency per week is missing/unknown. A negative value in change in generalized tonic-clonic (GTC) seizure frequency indicates a reduction of generalized tonic-clonic (GTC) seizure frequency over the Treatment Period.
Time frame: During the Treatment Period (up to 4.8 years)
The Incidence of Adverse Drug Reactions During the Entire Study Period
Adverse drug reactions excludes Adverse Events (AEs) described by the investigators with no relationship to study drug.
Time frame: Through study completion, an average of 3 years
This study started to enroll subjects in Japan in June 2011.
| Milestone | Levetiracetam |
|---|---|
| Started | 44 |
| Completed | 34 |
| Not completed | 10 |
| Withdrew: Withdrawal by subject | 4 |
| Withdrew: Ae, non-serious non-fatal | 4 |
| Withdrew: Withdrawal criteria no.3 | 1 |
| Withdrew: Subject moved a long distance | 1 |
| Treatment Emergent Adverse Events | Levetiracetam (SS) |
|---|---|
| Incidence of Treatment Emergent Adverse Events During the Entire Study Period | 626 |
Percentage change in generalized tonic-clonic (GTC) seizure frequency per week from Baseline of previous studies B over the Treatment Period A is calculated using the equation: Percentage change from Baseline = ((A-B)/B)\*100. Percentage change from baseline is not defined for subjects whose baseline information is missing / unknown or equal to zero, or whose seizure frequency per week is missing/unknown. A negative value in change in generalized tonic-clonic (GTC) seizure frequency indicates a reduction of generalized tonic-clonic (GTC) seizure frequency over the Treatment Period.
| percent change | Levetiracetam (FAS) |
|---|---|
| The Percentage Change in Generalized Tonic-Clonic (GTC) Seizure Frequency Per Week Over the Evaluation Period From Either of the Combined Baseline Periods of the Previous Studies (N01159 or N01363). | -92.07 (-97.16 to -64.64) |
Adverse drug reactions excludes Adverse Events (AEs) described by the investigators with no relationship to study drug.
| Adverse Drug Reactions | Levetiracetam (SS) |
|---|---|
| The Incidence of Adverse Drug Reactions During the Entire Study Period | 46 |
Collected over Adverse Events (AEs) were collected from Visit 1 (Week 0) until Safety Follow Up Visit (up to 4.7 years).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Levetiracetam (SS) | — | 13/44 (29.5%) | 41/44 (93.2%) |
| Event | Levetiracetam (SS) |
|---|---|
| InfluenzaInfections and infestations | 2/44 |
| Acute tonsillitisInfections and infestations | 1/44 |
| BronchitisInfections and infestations | 1/44 |
| BronchopneumoniaInfections and infestations | 1/44 |
| PharyngotonsillitisInfections and infestations | 1/44 |
| Pneumonia respiratory syncytial viralInfections and infestations | 1/44 |
| Postoperative wound infectionInfections and infestations | 1/44 |
| Cervical vertebral fractureInjury, poisoning and procedural complications | 1/44 |
| Femoral neck fractureInjury, poisoning and procedural complications | 1/44 |
| Medical observationInvestigations | 1/44 |
| Event | Levetiracetam (SS) |
|---|---|
| NasopharyngitisInfections and infestations | 35/44 |
| ConvulsionNervous system disorders | 16/44 |
| Dental cariesGastrointestinal disorders | 11/44 |
| SomnolenceNervous system disorders | 10/44 |
| InfluenzaInfections and infestations | 9/44 |
| HeadacheNervous system disorders | 9/44 |
| DiarrhoeaGastrointestinal disorders | 8/44 |
| PyrexiaGeneral disorders | 8/44 |
| ConstipationGastrointestinal disorders | 7/44 |
| ContusionInjury, poisoning and procedural complications | 7/44 |
The Baseline Characteristics refer to the Safety Set (SS) which consisted of all subjects who took at least one dose of study medication in this study.
| Age, Categorical(Participants) | Levetiracetam |
|---|---|
| <=18 years | 15 |
| Between 18 and 65 Years | 28 |
| >=65 years | 1 |
| Age, Continuous(years) | Levetiracetam |
|---|---|
| Mean | 26.1 ± 13.9 |
| Sex: Female, Male(Participants) | Levetiracetam |
|---|---|
| Female | 16 |
| Male | 28 |
The record gives a start of Jun 2011, a primary completion of Apr 2016 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levetiracetam